Study of the Effect of Probiotics on Respiratory Morbidity After Influenza Vaccination of Elderly in Nursing Homes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

737 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether probiotic treatment improves the protection against respiratory infections after influenza vaccination in elderly living in nursing homes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Probiotics and Influenza Vaccination Response

NCT05690373

Vaccine Response

COMPLETED NA

Probiotic, Prebiotic and Synbiotic Effect on Immunity

NCT01084434

Dietary Intervention

UNKNOWN NA

The Effect of Synbiotics on the Upper Respiratory Tract Infection

NCT04960878

Upper Respiratory Tract Infection Gut Microbiota Immune Function

COMPLETED NA

Use of Probiotics to Prevent Influenza

NCT01720329

Influenza

COMPLETED NA

Evaluation of Probiotics on Symptoms of Upper Respiratory Tract Infections

NCT00599430

Healthy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Influenza virus is a member of the orthomyxovirus family and causes an acute viral disease of the respiratory tract. The illness is usually self-limiting. Hospitalization and deaths mainly occur in high-risk groups (elderly, chronically ill). Response to vaccination is subject to high levels of variability due to age, stress, nutritional stage, etc.

Lactic acid bacteria are naturally commensal bacteria in the small and large intestines. These bacteria protect the host against potential pathogens by competitive exclusion and also by the production of antibacterial agents known as bacteriocins. It has only been recently shown that another mechanism whereby probiotic bacteria may provide a health benefit is by modulating immune responses.

Lactobacillus casei strain Shirota (LcS) is widely consumed in fermented milk products. Several studies, in animals as wells as in humans, report on the immunomodulatory functions of LcS.

The aim of this multicentre, randomized, placebo controlled, double blind study (RCT) is to assess if probiotic treatment with Lactobacillus casei Shirota improves the protection against influenza(-like) infections after vaccination with trivalent influenza vaccine in elderly residing in nursing homes.

Trial endpoints:

1. Clinical outcome: difference in incidence in upper respiratory tract infections (influenza-like illness)
2. Serological outcome: difference in influenza vaccine specific serum IgG between probiotic and control treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Tract Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lactobacillus casei Shirota

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy male and female volunteers of 65 years or older
* volunteers reside in residential homes
* volunteers must be willing to swallow Yakult/placebo 2x/day for 3 weeks prevaccination and 5 months follow-up
* participants must be able to comply with requirements of study (e.g. assessment of respiratory symptoms, Yakult/placebo administration)
* participants must read and sign written Informed Consent Form after the nature of the study has been fully explained

Exclusion Criteria

elderly with:

* any medical or practical condition which make the volunteer not suitable for participating in this study at discretion of the investigator
* any current relevant infectious disease
* any current known disorder having negative repercussions on the volunteer's immune system, such as auto-immune diseases, COPD requiring oxigen, cancer, chronic inflammatory disease
* allergy to influenza vaccine, eggs, neomycin, amphotericin B, erythromycin, amantadine
* ongoing treatment with immunosuppressive drugs, chemotherapeutics or other antineoplastic medication
* current use of antibiotics or use 6 weeks prior to study entry
* use of any investigative drug (other drugs who are also under investigation) within 90 days prior to study entry
* with markedly abnormal results in any of the screening laboratory tests

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes